NDA 016763 · Rising
Sulfamylon
Mafenide Acetate · Topical
Priority reviewOrphanLast checked: Nov 20, 2026Latest source record: Dec 13, 2002 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations
First approved
1969
Jan 24, 1969
Approved uses
1
Original approval plus efficacy supplements
Registered trials
4
1 Phase 3, 0 recruiting
FAERS reports
31
25 serious, 4 with death reported
AI brief across all sources
Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.
What it is approved for
From the label in effect Jul 3, 2023.
INDICATIONS AND USAGE SULFAMYLON Cream is a topical agent indicated for adjunctive therapy of patients with second- and third-degree burns.
Approval history
Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.
- Jan 24, 1969 Original approval · Type 2 - New Active Ingredient · priority review
1 products under this application
- SULFAMYLON · MAFENIDE ACETATE EQ 85MG BASE/GM · CREAM, TOPICAL · Prescription
Clinical trials
Interventional ClinicalTrials.gov studies with "Mafenide" as an intervention, any sponsor and status, largest first.
- Effects of Therapy With Sulfamylon® 5% Topical Solution Compared to a Historical Control GroupTerminated
Mylan Inc.Industry
NCT00634166 · 220 participants · Start Sep 2007 · Primary completion Dec 2013
Drug: Sulfamylon® For 5 % Topical Solution; Topical Antimicrobial/Antifungal Medications · For: Burns
Sites: Mobile, Alabama; Redlands, California; Gainesville, Florida · 9 sites in all
- Study of the Treatment of Burn Wounds With Antimicrobial Topical SoaksPivotal-lookingTerminated
The University of Texas Medical Branch, GalvestonAcademic, hospital or other
NCT00675922 · 98 participants · Start Jul 1995 · Primary completion May 2008
Drug: Sulfamylon 5% and Silver Nitrate Soaks · For: Burn
Sites: Galveston, Texas
- Vashe Wound Therapy StudyCompleted
Valleywise HealthAcademic, hospital or other
NCT00586729 · 23 participants · Start Jul 2009 · Primary completion Nov 2010
Drug: Mafenide acetate · For: Burns
Sites: Phoenix, Arizona
Julio RamirezAcademic, hospital or other
NCT02099240 · 11 participants · Start Mar 6, 2014 · Primary completion Nov 7, 2018
Drug: oral antibiotics · For: Osteomyelitis
Sites: Louisville, Kentucky
Most reported adverse reactions
FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.
- drug ineffective4
- pyrexia4
- sepsis4
- wound infection3
- agitation2
- anxiety2
- clostridium difficile colitis2
- dry skin2
- erythema2
- fatigue2
- gait disturbance2
- hypotension2
FAERS reports by year
By the date FDA received the report.
View as table
| Year | Reports |
|---|---|
| 2004 | 1 |
| 2005 | 1 |
| 2006 | 1 |
| 2008 | 1 |
| 2012 | 2 |
| 2014 | 1 |
| 2015 | 4 |
| 2016 | 4 |
| 2018 | 6 |
| 2019 | 2 |
| 2020 | 1 |
| 2021 | 2 |
| 2022 | 2 |
| 2023 | 1 |
| 2024 | 1 |
| 2025 | 1 |
Recalls
0 FDA enforcement reports for this application.
No recalls on record for this application.
Shortages
FDA's drug shortage list.
Not on FDA's shortage list.
Medicare spending
CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.
Part D: Sulfamylon (Mafenide Acetate)
2024 spending
$51K
Beneficiaries
297
447 claims
Per beneficiary
$172
$1.25 per unit
View as table
| Year | Spending |
|---|---|
| 2020 | $0 |
| 2021 | $15,730 |
| 2022 | $50,898 |
| 2023 | $52,452 |
| 2024 | $51,044 |
Published evidence
PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.
- Topical treatment for facial burns.
Hoogewerf CJ, Hop MJ, Nieuwenhuis MK, et al. · Cochrane Database Syst Rev 2020 · Research Support, Non-U.S. Gov't, Systematic Review
- A silver-coated antimicrobial barrier dressing used postoperatively on meshed autografts: a dressing comparison study.
Silver GM, Robertson SW, Halerz MM, et al. · J Burn Care Res 2007 · Comparative Study, Randomized Controlled Trial
- Efficacy of topical silver against fungal burn wound pathogens.
Wright JB, Lam K, Hansen D, et al. · Am J Infect Control 1999 · Clinical Trial, Comparative Study
- Studies of the pain produced by mafenide acetate preparations in burns.
Harrison HN, Shuck JM, Caldwell E · Arch Surg 1975 · Clinical Trial, Comparative Study
- Strategies to prevent suppurative chondritis following auricular burns: a systematic review.
Nasrallah F, Brewer CF, Arkoulis N, et al. · J Wound Care 2022 · Systematic Review
- Sulfamylon acetate in the treatment of pseudomonas pyocyanea infection of burns.
Muir IF, Owen D, Murphy J · Br J Plast Surg 1969 · Clinical Trial, Comparative Study
Sponsor: Rising
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.